Trevi Therapeutics, Inc. (TRVI) intrinsic value & 10-year financials
Trevi Therapeutics, Inc. (TRVI) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $11.88
- Market cap
- $1.6B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 37.7%
- Free cash flow (FY2025)
- -$42.1M
TRVI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$42.8M | -$0.32 | -$42.1M | — | -42.6% |
| FY2024 | — | -$47.9M | -$0.47 | -$38.3M | — | -87.7% |
| FY2023 | — | -$29.1M | -$0.29 | -$31.8M | — | -46.4% |
| FY2022 | — | -$29.2M | -$0.45 | -$28.3M | — | -79.5% |
| FY2021 | — | -$33.9M | -$1.49 | — | — | 174.0% |
| FY2020 | — | -$32.8M | — | -$29.0M | — | 323.3% |
| FY2019 | — | -$26.1M | — | -$23.1M | — | 44.7% |
| FY2018 | — | -$20.5M | — | -$18.4M | — | 15.7% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Trevi Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Trevi Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -23.9% ROIC.
Trevi Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Trevi Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.